FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة الأكواد

Longevity Foundation

Anti-Aging & Longevityintermediate

91

التعاون

91
Share
البروتيدات

3

متوسط الجرعة اليومية (mcg)

12,000

المستوى

intermediate

تمت الإضافة

May 17, 2026

نظرة عامة

The Longevity Foundation stack addresses three fundamental pillars of biological aging: telomere attrition, extracellular matrix degradation, and immune senescence. Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It activates telomerase — the enzyme that rebuilds telomere caps on chromosomes — in somatic cells. In Khavinson''s clinical studies, Epithalon administration to elderly patients was associated with reduced mortality, improved immune markers, and normalization of melatonin production from the pineal gland. It is administered in 10-day cycles, typically twice per year. GHK-Cu is a naturally occurring copper-binding tripeptide that functions as a master regulator of tissue remodeling. Beyond its surface-level skin benefits, GHK-Cu modulates the expression of over 4,000 genes — many involved in DNA repair, antioxidant production (SOD, glutathione), stem cell proliferation, and suppression of pro-inflammatory cytokines. Its concentration in human plasma drops from 200 ng/mL at age 20 to 80 ng/mL by age 60, correlating with visible aging and reduced regenerative capacity. Thymosin Alpha-1 addresses immunosenescence — the progressive decline of immune function with age that increases susceptibility to infections, cancer, and autoimmune conditions. By promoting T-cell maturation, dendritic cell activation, and natural killer cell function, Ta1 helps restore immune surveillance to more youthful levels. The three-peptide combination creates a comprehensive anti-aging protocol: Epithalon maintains chromosomal integrity, GHK-Cu restores tissue remodeling capacity and gene expression patterns, and Thymosin Alpha-1 rejuvenates immune competence. This represents a systems-biology approach to aging rather than targeting any single pathway.

بروتوكول الجرعة

Epithalon

daily (10-day cycle)· subcutaneous

قراءة المزيد عن Epithalon →

10,000 mcg

كل جرعة

GHK-Cu

Every day· subcutaneous

قراءة المزيد عن GHK-Cu →

500 mcg

كل جرعة

Thymosin Alpha-1

2x/week· subcutaneous

قراءة المزيد عن Thymosin Alpha-1 →

1,500 mcg

كل جرعة

الأهداف والدليل

Telomere lengthImmune functionSkin qualityAnti-agingLongevity
درجة الدليل:بيانات بشرية

تحذيرات

  • Epithalon and GHK-Cu were removed from the FDA Category 2 list (April 2026) but remain pending PCAC review — not legal to compound yet. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad as Zadaxin). Epithalon cycles: 10 days on, 6 months off.

Comments

Sign in to join the discussion

تحذير: هذا الكود مقدم من قبل المجتمع ويهدف لغرض البحث فقط. لا يتحقق Peptide Contacts من سلامة أو فعالية الأكواد المقدمة. استشر محترف صحي مؤهل قبل استخدام أي بروتوكول بروتيني.